Teva Pharmaceuticals
U.S. Headquarters
1090 Horsham Road
North Wales
Pennsylvania
19454
United States
Tel: 888-838-2872
Website: https://www.tevausa.com/
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
YEAR FOUNDED:
1901
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1550 articles with Teva Pharmaceuticals
-
Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation
10/21/2019
Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties’ claims and removes Teva from the Track 1 opioid litigation.
-
As an historic lawsuit over opioids was to enter court today, four key defendants reached a settlement.
-
This shortage could force many treating physicians to begin making tough choices on how to address cancers in their patients.
-
Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019
10/7/2019
Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
-
Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019
10/2/2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
-
Teva Announces Leadership Change in its Global Operations Group
10/2/2019
Teva Pharmaceutical Industries announced the retirement of Dr. Carlo de Notaristefani, and the appointment of Eric Drapé as Executive Vice President, Global Operations.
-
INTERCURE: CANNDOC signs strategic distribution agreement with S.L.E. of TEVA Pharmaceuticals
9/13/2019
InterCure, announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein which is owned by Teva Pharmaceuticals Industries.
-
Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society - Sept. 4, 2019
9/4/2019
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
-
Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
9/3/2019
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
-
Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory Council
9/3/2019
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that the U.S. Department of Commerce has selected Brendan O’Grady, Executive Vice President and Head of North America Commercial to serve on the U.S. Investment Advisory Council.
-
Clinical Catch-up for August 19-23
8/26/2019
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week. -
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
-
Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine
8/21/2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet.
-
SHAREHOLDER ALERT - Teva Pharmaceutical Industries Ltd. (TEVA) - Bronstein, Gewirtz & Grossman, LLC Alerts Stockholders of Class Action and Lead Plaintiff Deadline: August 20, 2019
8/20/2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Teva Pharmaceutical Industries Ltd. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Teva American Depositary Shares between August 4, 2017 and May 10, 2019, inclusive.
-
Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States
8/20/2019
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S.
-
BioSpace Movers and Shakers, Aug. 9
8/9/2019
Biopharma companies strengthen their senior leadership teams and boards of directors. -
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
-
CORRECTING and REPLACING Alcoholic Hepatitis Treatment Market Worth USD 570 Million, at 6% CAGR during 2019-2023 | Technavio
7/16/2019
According to Technavio Research Report "Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others), and geographic regions (North America, Europe, Asia, and ROW) is witnessed to grow by USD 570 million, at a CAGR of 6% from 2019 to 2023”.
-
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
7/2/2019
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
-
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd
6/27/2019
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 20, 2019 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE: TEVA), if they purchased the Company's American Depository Shares ("ADS") between August 4, 2017 and May 10, 2019, inclusive (the "Class Period").